NICE recommends Enhertu for advanced breast cancer

Date:

Share post:

The National Institute for Health and Care Excellence (NICE) has recommended Enhertu for people with advance breast cancer.

“There is not enough evidence yet to show how much longer people live with Enhertu compared with trastuzumab emtansine because the clinical trial is still ongoing. This means the cost-effectiveness estimates are highly uncertain and Enhertu cannot be recommended for routine use in the NHS,” said NICE.

The independent appraisal committee concluded that Enhertu could be cost-effective if further evidence from the ongoing trial and from NHS practice can show how much longer people live with treatment.

Helen Knight, director of medicines evaluation at NICE, said: “Today’s draft guidance is good news for people with this type of advanced breast cancer, who often experience severe and debilitating symptoms.

“It also means NICE has made positive recommendations in all 18 of its appraisals of breast cancer medicines since March 2018. These are all now available for clinicians to use in the treatment of thousands of NHS patients and demonstrate how NICE works successfully at the interface of health and care and the life sciences industry to enable early access to innovation.”

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...